Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Latest Press Releases
Evaluate Vantage 2020 Review: Biopharma IPOs and venture financing break records; global drug stocks add half a trillion dollars in market capitalization
The top 600 biopharma firms added $487 billion in market capitalisation in 2020, according to the Evaluate Vantage Pharma, Biotech & Medtech 2020 in Review report,…
Inova and BIO, in partnership with Evaluate, announce a new series of therapeutic-specific Virtual Partnering events for 2021
Inova and the Biotechnology Innovation Organization (BIO), in partnership with Evaluate announce the second annual series of Virtual Partnering events focused on critical…
Evaluate Vantage 2021 Preview: High hopes and valuations set the tone for biopharma
COVID-19 will continue to be a defining issue for pharma and biotech companies in 2021, but overall the sector will start the year from a position of strength, according…
Browse the archive
Evaluate Vantage 2020 Preview: Strong sales and product launches set the stage for biopharma growth, but underlying market concerns exist
Oncology dominates the growth outlook for pharma; four of the eight drugs expected to add $1bn or more in new sales next year are for cancer, according to the Evaluate…
Evaluate Ltd. appoints Martyn Hindley as Chief Financial Officer
Evaluate Ltd., the leading provider of commercial data to the life sciences industry, is pleased to announce the appointment of Martyn Hindley as Chief Financial Officer,…
Evaluate Ltd. transforms pharma R&D risk assessment with launch of Product Specific PTRS
Breakthrough offering combines the power of machine learning with the transparency of Evaluate’s renowned analytical approach for the most accurate analysis of drug…
Evaluate Vantage Half-Year Review 2019: Pharma and medtech mega-deals mask drop in M&A activity
The report, published today, analyses stock and market performance, M&A and the financing landscape during the first half of 2019
Innovation and unmet need drive prescription drug sales to $1.18tr by 2024: new report from Evaluate Ltd
“EvaluatePharma® World Preview 2019, Outlook to 2024” explores growth drivers, growth brakes and top industry performers.
The “one and done” era for orphan drugs: Evaluate predicts 12% growth, driven by new technologies, but benefits go to big pharma
Orphan drug sales reach $242bn by 2024, according to EvaluatePharma® Orphan Drug Report 2019
Biopharma in 2018: A year of contrasts as stocks and M&A slump, but venture financing and IPOs remain strong
Evaluate Vantage releases annual analysis of Pharma, Biotech and Medtech performance
Uncertainty for pharma and biotech in 2019 as sector stumbles at the end of 2018
Vantage’s Annual Pharma and Biotech Preview explores what’s in store for 2019
Worldwide medtech sales forecast to reach $595 billion by 2024, with a CAGR of 5.6%, anchored by familiar players
Evaluate Ltd. releases annual “EvaluateMedtech World Preview 2018, Outlook to 2024” in conjunction with The Medtech Conference
